Carcinomas News and Research

RSS

DUSA Pharmaceuticals finds place in Deloitte's Technology Fast 500 list for second consecutive year

DUSA Pharmaceuticals, Inc.(R)( )(Nasdaq: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that it has been named to Deloitte's Technology Fast 500 list. For the second consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications and life sciences companies in North America in terms of percentage revenue growth over a five year period.

21 Oct 2009

Clonality analyses may lead to further understanding of hepatocarcinogenesis

Focal nodular hyperplasia (FNH) is a lesion found in an otherwise normal liver, and is considered to be parenchyma overgrowth responsive to increased blood flow secondary to vascular malformations.

20 Oct 2009

Prometheus Laboratories introduces three new cancer diagnostic products

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the nationwide commercial launch of three new cancer diagnostic products: ProOnc TumorSource Dx, ProOnc Squamous Dx and ProOnc Mesothelioma Dx. Each of these tests is based on recently developed, highly sensitive microRNA technology.

15 Oct 2009

M. D. Anderson Cancer Center researchers announce study results of treatment for rare pediatric brain cancer

A team of researchers led by The University of Texas M. D. Anderson Cancer Center unveiled results today from the largest-ever collaborative study addressing the treatment of a rare pediatric brain tumor. The findings suggest a new standard protocol could improve survival nearly two-fold for pediatric patients with choroid plexus tumors, as reported at the 41st Annual Meeting of the International Society of Pediatric Oncology (SIOP).

12 Oct 2009

Manual microdissection to remove biopsy cavities from breast cancer specimens essential

Genomic Health, Inc. today announced results from a study demonstrating the critical role of manual microdissection to remove all biopsy cavities from breast cancer specimens. Genomic Health's Oncotype DX is the only commercially available breast cancer test that employs manual microdissection following review by a board certified surgical pathologist with breast expertise to predict a patient's benefit from chemotherapy and risk of disease recurrence.

9 Oct 2009

Study finds BSGI to be a cost-effective breast diagnostic imaging modality

Breast-Specific Gamma Imaging (BSGI), a molecular breast imaging technique with comparable sensitivity to breast magnetic resonance imaging (MRI) for detecting breast carcinoma when used in pre-surgical planning for patients with known cancer diagnoses and is substantially less expensive than MRI, according to findings presented today at the American Society of Clinical Oncology Breast Cancer Symposium in San Francisco, California.

9 Oct 2009

Combination of medications and light therapy effective against head and neck cancers

A combination of medications and a particular light therapy is effective at treating certain types of head and neck cancers in subtropical climates.

5 Oct 2009

Study reveals microRNAs affect tumor progression

UCSF researchers have identified collections of tiny molecules known as microRNAs that affect distinct processes critical for the progression of cancer. The findings, they say, expand researchers' understanding of the important regulatory function of microRNAs in tumor biology and point to new directions for future study and potential treatments.

18 Sep 2009

Molecular mechanism responsible for transition of non-invasive breast cancer into invasive disease discovered

Active, but non-invasive breast cancer is set free to roam as invasive breast cancer when an overexpressed protein converts it to a different cell type, scientists at The University of Texas M. D. Anderson Cancer Center report in the Sept. 9 issue of the journal Cancer Cell.

9 Sep 2009

Study to test efficacy of lapatinib in advanced hepatocellular carcinoma

Use of the molecularly targeted agent lapatinib to delay tumor growth and improve the survival of patients with inoperable hepatocellular carcinoma, or liver cancer, only benefited certain subgroups of patients. While results of this study were largely negative, patients that exhibited toxicity from the drug in the form of a skin rash appeared to have a greater tumor response and longer survival.

9 Sep 2009

Invasive front dominant expression of LNγ2 and LNβ3 and active MMP7 play a key role in biliary tract cancer

Despite recent advances in diagnosis and treatment, the prognosis of patients with biliary tract cancer is still poor. Elucidating the biological characteristics of these carcinomas has become necessary to improve the prognosis of patients and to devise better treatment strategies. A recent study report that invasive front dominant expression of LNγ2 and LNβ3 and active MMP7 play a key role in the progression of biliary tract cancer.

26 Aug 2009

Elevated levels of GLI1 protein linked to unfavorable prognosis and progressive stages in human breast cancer

Elevated levels of GLI1 (glioma-associated oncogene homolog 1) protein in human breast cancer are associated with unfavorable prognosis and progressive stages of disease. Researchers writing in the open access journal BMC Cancer found increased expression of GLI1 in samples taken from more advanced and less survivable tumors.

25 Aug 2009

New technique may help clinicians in diagnosing pleural effusion

A new technique may help clinicians hone in on a diagnosis in patients presenting with a pleural effusion of unknown cause.

24 Aug 2009

Discovery of novel tumor suppressor

4 Aug 2009

Discovery of novel tumor suppressor

La Jolla Institute for Allergy & Immunology researchers studying an enzyme believed to play a role in allergy onset, instead have discovered its previously unknown role as a tumor suppressor that may be important in myeloproliferative diseases and some types of lymphoma and leukemia. Myeloproliferative diseases are a group of disorders characterized by an overproduction of blood cells by the bone marrow and include chronic myeloid leukemia. Lymphoma and leukemia are cancers of the blood.

3 Aug 2009

New breast biopsy technique

Researchers have developed a new breast biopsy technique that could lead to decreased procedure times and reduced patient discomfort and morbidity, according to a study performed at Roberts Research Institute, the University of Western Ontario and London Health Sciences Centre, London, ON, Canada.

24 Jun 2009

Non-toxic radioactive patch successfully treats skin cancer

A new study shows that a radioactive skin patch can safely and successfully treat basal cell carcinoma, one of the most common types of skin cancers, according to researchers at the SNM's 56th Annual Meeting. The skin patch, which delivers the radioactive phosphorus-32, is nontoxic and could be an excellent alternative to surgery or radiotherapy in cases where carrying out these treatments is difficult.

15 Jun 2009

New lung cancer therapy with vaporized viral vector shows promise

A new lung cancer therapy employing a vaporized viral vector to deliver a cancer-inhibiting molecule directly to lung tissue shows early promise in mouse trials, according to researchers at the Ministry of Education, Science and Technology in Korea.

9 Jun 2009

Sun-damaged rough patches or lesions on the skin lead to more cancer types than once believed

Actinic keratoses are sun-damaged rough patches or lesions on the skin - often pink and scaly - that doctors have long believed can turn into a form of skin cancer known as squamous cell carcinoma.

2 Jun 2009

To spread, skin cancer attacks immune dendritic cells

Dendritic cells are the sentinels of the immune system. When they're alert and on guard, they will marshal the body's immunosoldiers, T cells, to battle at the sight of harmful pathogens. But some diseases, such as cancer, are able to escape their watchful eye. By knocking out or beguiling dendritic cells, they slip the defenses of the immune system and sack the unsuspecting body.

27 May 2009

Carcinomas News and Research

DUSA Pharmaceuticals finds place in Deloitte's Technology Fast 500 list for second consecutive year

Clonality analyses may lead to further understanding of hepatocarcinogenesis

Prometheus Laboratories introduces three new cancer diagnostic products

M. D. Anderson Cancer Center researchers announce study results of treatment for rare pediatric brain cancer

Manual microdissection to remove biopsy cavities from breast cancer specimens essential

Study finds BSGI to be a cost-effective breast diagnostic imaging modality

Combination of medications and light therapy effective against head and neck cancers

Study reveals microRNAs affect tumor progression

Molecular mechanism responsible for transition of non-invasive breast cancer into invasive disease discovered

Study to test efficacy of lapatinib in advanced hepatocellular carcinoma

Invasive front dominant expression of LNγ2 and LNβ3 and active MMP7 play a key role in biliary tract cancer

Elevated levels of GLI1 protein linked to unfavorable prognosis and progressive stages in human breast cancer

New technique may help clinicians in diagnosing pleural effusion

Discovery of novel tumor suppressor

Discovery of novel tumor suppressor

New breast biopsy technique

Non-toxic radioactive patch successfully treats skin cancer

New lung cancer therapy with vaporized viral vector shows promise

Sun-damaged rough patches or lesions on the skin lead to more cancer types than once believed

To spread, skin cancer attacks immune dendritic cells

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News